Cleveland Clinic Mesothelioma Treatment Program

If you or someone you love has been diagnosed with mesothelioma, finding a high-volume specialty center can make a real difference in your options and outcomes. Cleveland Clinic, one of the most recognized academic medical centers in the United States, operates a dedicated mesothelioma treatment program through its Taussig Cancer Institute and Department of Thoracic and Cardiovascular Surgery. The program brings together surgeons, oncologists, radiologists, and palliative care specialists who focus specifically on the rare cancers caused by asbestos exposure.

Mesothelioma is a malignant tumor arising from the mesothelial cells lining the lungs, abdomen, or heart. According to the National Cancer Institute (NCI), approximately 3,000 new cases are diagnosed in the United States each year, making it rare enough that most community hospitals see only a handful of cases annually. That's precisely why centers like Cleveland Clinic matter: their surgeons and oncologists manage a concentrated volume of mesothelioma cases, which translates directly into deeper institutional expertise.

Cleveland Clinic's mesothelioma program is built around a tumor board model, meaning that every new patient's case is reviewed by specialists from multiple disciplines before a treatment plan is finalized. According to Cleveland Clinic's own published patient care guidelines, this collaborative review process helps ensure that surgery, chemotherapy, radiation, and emerging immunotherapy options are all considered in combination, rather than in isolation. For patients diagnosed at a community hospital, seeking a second opinion at Cleveland Clinic is a common and strongly encouraged step.

The program serves patients with pleural mesothelioma, peritoneal mesothelioma, and the rarer pericardial and testicular forms. Each subtype requires a distinct surgical and oncological approach, and Cleveland Clinic's team has documented experience across all of them.

Cleveland Clinic's mesothelioma specialists treat all four recognized subtypes of the disease, though the majority of their caseload involves pleural mesothelioma, which accounts for roughly 75 to 80 percent of all diagnoses according to the NCI's Mesothelioma Treatment PDQ.

For pleural mesothelioma, the thoracic surgery team evaluates patients for two primary surgical approaches: extrapleural pneumonectomy (EPP), which removes the affected lung entirely along with surrounding tissue, and pleurectomy/decortication (P/D), a lung-sparing procedure that removes the pleural lining and visible tumor while preserving the underlying lung. Cleveland Clinic surgeons have published research and commentary on the ongoing debate between these two procedures, generally favoring P/D in patients who are surgical candidates, based on comparable survival data with lower operative mortality.

For peritoneal mesothelioma, Cleveland Clinic offers cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC), a procedure in which heated chemotherapy drugs are circulated directly through the abdominal cavity after visible tumor removal. According to a landmark study published in the Journal of Clinical Oncology in 2003 by Sugarbaker et al., patients who underwent cytoreduction with HIPEC achieved median survival times exceeding five years in select cases, a dramatic improvement over systemic chemotherapy alone.

Pericardial and testicular mesothelioma are exceptionally rare, and Cleveland Clinic's multidisciplinary team approaches these on a case-by-case basis, often drawing on the broader oncology literature and tumor board input from multiple subspecialties.

Imagine receiving a chest X-ray result showing unexplained fluid around your lungs, followed by a CT scan that raises concern for a pleural mass. This is the path many mesothelioma patients walk before they ever hear the word "mesothelioma." At Cleveland Clinic, the diagnostic workup is designed to move efficiently from imaging to tissue confirmation, because mesothelioma's symptoms overlap significantly with other conditions, including lung cancer, benign pleural disease, and even pneumonia.

Cleveland Clinic's diagnostic process typically begins with advanced imaging. The radiology team uses high-resolution CT scans, PET scans, and in selected cases MRI to characterize the extent and location of disease. According to the NCI, no imaging modality alone can confirm mesothelioma; tissue biopsy remains the diagnostic gold standard.

For tissue acquisition, Cleveland Clinic's thoracic surgeons and interventional pulmonologists perform several procedures depending on the clinical picture. Video-assisted thoracoscopic surgery (VATS) is the preferred method for pleural biopsies, as it allows direct visualization of the pleural surface and collection of adequate tissue for pathological analysis. For patients who cannot tolerate surgery, CT-guided needle biopsy or thoracentesis (fluid sampling) may be performed, though these carry a higher rate of non-diagnostic results in mesothelioma specifically.

Pathological diagnosis at Cleveland Clinic is performed by thoracic pathologists with subspecialty expertise. Mesothelioma must be distinguished from adenocarcinoma of the lung and other pleural tumors using immunohistochemistry (IHC) panels. According to the Archives of Pathology and Laboratory Medicine (2018), a combination of positive markers (calretinin, WT-1, D2-40) and negative markers (CEA, TTF-1) is used to confirm a mesothelioma diagnosis. Cleveland Clinic's pathology department also performs BAP1 and MTAP testing, newer molecular markers that help distinguish malignant mesothelioma from benign mesothelial proliferations, a distinction that carries profound clinical and legal implications for patients.

Once the diagnosis is confirmed, staging is completed using the TNM staging system endorsed by the American Joint Committee on Cancer (AJCC). Cleveland Clinic's tumor board then convenes to review the full diagnostic picture before recommending a treatment strategy.

Cleveland Clinic's treatment philosophy for mesothelioma centers on a concept the oncology literature calls "multimodality therapy," meaning the intentional combination of surgery, chemotherapy, and radiation rather than relying on any single modality. This approach, championed by centers like Cleveland Clinic, the Brigham and Women's Hospital, and Memorial Sloan Kettering, reflects decades of evidence that no single treatment alone achieves meaningful long-term disease control in most mesothelioma patients.

Surgery

For patients with early-stage pleural mesothelioma who are medically fit, surgery remains the cornerstone of potentially curative treatment. Cleveland Clinic's thoracic surgery division performs both EPP and P/D, with patient selection guided by pulmonary function tests, cardiac evaluation, and disease staging. A 2020 analysis published in JTCVS Open found that P/D was associated with lower 30-day mortality compared to EPP (approximately 2 to 3 percent versus 5 to 8 percent at high-volume centers), supporting a trend toward lung-sparing approaches at institutions like Cleveland Clinic.

Chemotherapy

The standard first-line chemotherapy regimen for mesothelioma, established by the pivotal Phase III trial published by Vogelzang et al. in the Journal of Clinical Oncology in 2003, is pemetrexed (Alimta) combined with cisplatin. This combination demonstrated a median overall survival of 12.1 months compared to 9.3 months for cisplatin alone. Cleveland Clinic's medical oncologists administer this regimen for patients who are not surgical candidates or as adjuvant therapy following surgery. Carboplatin is often substituted for cisplatin in patients with kidney impairment or who cannot tolerate cisplatin's side effects.

Immunotherapy

One of the most significant recent advances in mesothelioma treatment is the approval of nivolumab plus ipilimumab (Opdivo/Yervoy) by the U.S. Food and Drug Administration in October 2020 for unresectable pleural mesothelioma. This approval was based on the CheckMate 743 trial, published in The Lancet in 2021, which showed a median overall survival of 18.1 months with dual immunotherapy compared to 14.1 months with standard chemotherapy. Cleveland Clinic's oncology team incorporates this regimen into their treatment algorithm for appropriate patients, particularly those with non-epithelioid histology, who showed the greatest benefit in the trial.

Radiation Therapy

Radiation plays a supporting role in mesothelioma treatment at Cleveland Clinic, primarily used to prevent tumor seeding at biopsy sites, to palliate pain from chest wall invasion, or as part of a multimodality protocol following surgery. Intensity-modulated radiation therapy (IMRT) and proton therapy are available at Cleveland Clinic, allowing precise dose delivery while minimizing exposure to the heart and remaining lung tissue.

Clinical Trials

Through the Taussig Cancer Institute, Cleveland Clinic actively enrolls mesothelioma patients in clinical trials investigating novel agents, including targeted therapies, CAR-T cell approaches, and combination immunotherapy regimens. Patients can search available trials through the ClinicalTrials.gov database using Cleveland Clinic as the site filter.

Prognosis for mesothelioma remains challenging regardless of where treatment is received, but volume of experience at a treating institution does influence outcomes. According to the NCI, the overall five-year survival rate for pleural mesothelioma is approximately 10 percent, though this figure encompasses all stages and histological subtypes. Patients with epithelioid mesothelioma (the most common cell type, accounting for roughly 60 percent of cases) consistently show better outcomes than those with sarcomatoid or biphasic subtypes.

Several factors influence individual prognosis at Cleveland Clinic and elsewhere. Earlier stage at diagnosis, epithelioid cell type, good performance status, and eligibility for surgical resection are all associated with longer survival. A 2019 retrospective study published in Annals of Thoracic Surgery found that patients undergoing P/D at high-volume thoracic surgery centers achieved median survival times of 20 to 29 months for epithelioid disease, compared to historical benchmarks of 12 to 14 months with chemotherapy alone.

For peritoneal mesothelioma treated with cytoreductive surgery and HIPEC, prognosis is considerably more favorable. Studies from specialized centers have reported five-year survival rates of 40 to 50 percent in carefully selected patients, according to data compiled by the Peritoneal Surface Oncology Group International.

Cleveland Clinic encourages patients to discuss their individual prognostic factors openly with their care team, recognizing that survival statistics describe populations, not individuals. As one Cleveland Clinic thoracic oncologist has noted in published commentary, "Every patient who walks through our door has a story that the statistics don't capture. Our job is to give them the best possible version of their story."

A mesothelioma diagnosis reshapes every aspect of daily life, from managing treatment side effects to navigating the financial and legal questions that often accompany an asbestos-related cancer. Cleveland Clinic's program includes dedicated support services to address these dimensions of care alongside the medical treatment itself.

The Taussig Cancer Institute offers access to oncology social workers who help patients and families coordinate care, apply for financial assistance programs, and connect with community resources. Palliative care specialists are integrated into the mesothelioma team from the point of diagnosis, not just at end of life, to manage symptoms such as dyspnea (shortness of breath), chest pain, and fatigue that frequently accompany both the disease and its treatment.

Pulmonary rehabilitation is available for patients who have undergone surgical resection and need structured support to rebuild breathing capacity and physical endurance. Cleveland Clinic's rehabilitation medicine team works closely with thoracic surgery to design individualized recovery programs.

Many mesothelioma patients also have legal rights related to their asbestos exposure, and Cleveland Clinic's social work team can connect patients with resources for understanding those options. Asbestos trust funds, established by bankrupt asbestos manufacturers, have paid out more than $20 billion to claimants since the 1980s, according to the RAND Corporation's 2010 analysis of asbestos litigation. Consulting with a mesothelioma attorney is a separate step from medical care, but one that many patients pursue in parallel.